Single nucleotide polymorphism of GSTP1 and pathological complete response in locally advanced rectal cancer patients treated with neoadjuvant concomitant radiochemotherapy

다국어 초록 (Multilingual Abstract)

Purpose: Standard treatment for locally advanced rectal cancer consists of neoadjuvant radiochemotherapy with concomitant fluoropyrimidine or oxaliplatin and surgery with curative intent. Pathological complete response has shown to be predictive for better outcome and survival; nevertheless there are no biological or genetic factors predictive for response to treatment. We explored the correlation between the single nucleotide polymorphisms (SNPs) GSTP1 (A313G) and XRCC1 (G28152A), and the pathological complete response and survival after neoadjuvant radiochemotherapy in locally advanced rectal cancer patients.
Materials and Methods: Genotypes GSTP1 (A313G) and XRCC1 (G28152A) were determined by pyrosequencing technology in 80 patients affected by locally advanced rectal cancer.
Results: The overall rate of pathological complete response in our study population was 18.75%. Patients homozygous AA for GSTP1 (A313G) presented a rate of pathological complete response of 26.6% as compared to 8.5% of the AG+GG population (p = 0.04). The heterozygous comparison (AA vs. AG) showed a significant difference in the rate of pathological complete response (26.6% vs. 6.8%; p = 0.034). GSTP1 AA+AG patients presented a 5- and 8-year cancer-specific survival longer than GSTP1 GG patients (87.7% and 83.3% vs. 44.4% and 44.4%, respectively) (p = 0.014). Overall survival showed only a trend toward significance in favor of the haplotypes GSTP1 AA+AG. No significant correlations were found for XRCC1 (G28152A).
Conclusion: Our results suggest that GSTP1 (A313G) may predict a higher rate of pathological complete response after neoadjuvant radiochemotherapy and a better outcome, and should be considered in a more extensive analysis with the aim of personalization of radiation treatment.

목차 (Table of Contents)

• Introduction
• Materials and Methods
• Results

참고문헌 (Reference)

1 Di Simone D, "c-Jun and GST-pi expression in human plasma cells" 82 : 69-70, 1997

2 Cecchin E, "Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy" 11 : 214-226, 2011

3 Janjan NA, "Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience" 44 : 1027-1038, 1999

4 Borchiellini D, "The impact of pharmacogenetics on radiation therapy outcome in cancer patients: a focus on DNA damage response genes" 38 : 737-759, 2012

5 Zhang H, "TNF rs1799964 as a predictive factor of acute toxicities in Chinese rectal cancer patients treated with chemoradiotherapy" 94 : e1955-, 2015

6 Smith JJ, "Single nucleotide polymorphism TGFβ1 R25P correlates with acute toxicity during neoadjuvant chemoradiotherapy in rectal cancer patients" 97 : 924-930, 2017

7 Losi L, "Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy" 21 : 645-651, 2006

8 Kim DY, "Pretreatment selection of regimen according to genetic analysis improves the efficacy of chemotherapy in the first line treatment of metastatic colorectal cancer" 109 : 250-254, 2014

9 Kim JS, "Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer" 54 : 403-408, 2002

10 Osti MF, "Potential role of single nucleotide polymorphisms of XRCC1, XRCC3, and RAD51 in predicting acute toxicity in rectal cancer patients treated with preoperative radiochemotherapy" 40 : 535-542, 2017

11 Mahimkar MB, "Polymorphisms in GSTM1 and XPD genes predict clinical outcome in advanced oral cancer patients treated with postoperative radiotherapy" 51 (51): E94-E103, 2012

12 Paez D, "Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy:polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes" 81 : 1319-1327, 2011

13 Bohanes P, "Pharmacogenetic analysis of INT 0144 Trial: association of polymorphisms with survival and toxicity in rectal cancer patients treated with 5-FU and radiation" 21 : 1583-1590, 2015

14 Balboa E, "Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer:high incidence of somatic mutations and their relation with response" 11 : 747-761, 2010

15 Rodel C, "Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial" 16 : 979-989, 2015

16 Bujko K, "Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer" 93 : 1215-1223, 2006

17 Maas M, "Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data" 11 : 835-844, 2010

18 Kitade H, "Long-term administration and efficacy of oxaliplatin with no neurotoxicity in a patient with rectal cancer: association between neurotoxicity and the GSTP1 polymorphism" 7 : 1499-1502, 2014

19 Harries LW, "Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer" 18 : 641-644, 1997

20 Watson MA, "Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution" 19 : 275-280, 1998

21 Okcu MF, "Glutathione S-transferase polymorphisms and survival in primary malignant glioma" 10 : 2618-2625, 2004

22 Abbas M, "Glutathione S-transferase gene polymorphisms and treatment outcome in cervical cancer patients under concomitant chemoradiation" 10 : e0142501-, 2015

23 Agostini M, "Glutathione S-transferase P1 Ile105Val polymorphism is associated with haematological toxicity in elderly rectal cancer patients receiving preoperative chemoradiotherapy" 25 : 531-539, 2008

24 Sweeney C, "Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients" 12 : 527-533, 2003

25 Ates NA, "Glutathione S-transferase M1, T1, P1 genotypes and risk for development of colorectal cancer" 43 : 149-163, 2005

26 Edvardsen H, "Germline glutathione S-transferase variants in breast cancer:relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy" 67 : 1163-1171, 2007

27 Wang J, "Genetic polymorphisms of glutathione S-transferase genes and susceptibility to colorectal cancer: a case-control study in an Indian population" 35 : 66-72, 2011

28 Au WW, "Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays" 111 : 1843-1850, 2003

29 Wang Y, "From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity" 2 : 901-908, 2003

30 Srivastava SK, "Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa" 366 : 89-94, 1999

31 Bartelink H, "Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups" 15 : 2040-2049, 1997

32 Siegel R, "Colorectal cancer statistics, 2014" 64 : 104-117, 2014

33 Bosset JF, "Chemotherapy with preoperative radiotherapy in rectal cancer" 355 : 1114-1123, 2006

34 Damaraju S, "Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer" 12 : 2545-2554, 2006

35 Mandola MV, "A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity" 63 : 2898-2904, 2003